Click on image to view larger version.

Figure 3 Stratified Analyses of Aggregate 30-Day Costs by Treatment Group According to Pre-Specified Patient Characteristics

The graph indicates the mean difference in costs between the bivalirudin and heparin (unfractionated or low molecular weight heparin) + upstream glycoprotein IIb/IIIa receptor inhibitor (GPI) (black squares) along with the associated 95% confidence interval (bars). No interaction p values were significant, indicating that the overall treatment effect represents the most meaningful treatment effect for these subgroups (all p values for interaction >0.05).